Detalhe da pesquisa
1.
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
Int J Cancer
; 144(12): 3146-3159, 2019 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30536898
2.
Meeting report--3rd Neuroblastoma Research Symposium, Liverpool, 6-7th November, 2013.
Pediatr Blood Cancer
; 61(9): 1711-3, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24803179
3.
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
Clin Cancer Res
; 29(7): 1317-1331, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36602782
4.
Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells.
Cancers (Basel)
; 13(24)2021 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34944835
5.
Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma.
Front Oncol
; 10: 371, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32309213
6.
ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms.
Cancers (Basel)
; 12(5)2020 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32354033
7.
Detection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic Biomarkers.
Clin Cancer Res
; 26(1): 122-134, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31767563
8.
Assessment of sleep quality using cardiopulmonary coupling analysis in patients with Parkinson's disease.
Brain Behav
; 8(5): e00970, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29761019
9.
Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
Int J Oncol
; 52(3): 967-977, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29393340
10.
Meta-Analysis of Visual Evoked Potential and Parkinson's Disease.
Parkinsons Dis
; 2018: 3201308, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30123489
11.
Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
Oncotarget
; 7(52): 87301-87311, 2016 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-27888620
12.
SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.
Cancer Lett
; 363(1): 37-45, 2015 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25843293
13.
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
Oncotarget
; 6(12): 10207-21, 2015 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25844600
14.
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
Front Oncol
; 2: 173, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23226679
15.
p53 is a direct transcriptional target of MYCN in neuroblastoma.
Cancer Res
; 70(4): 1377-88, 2010 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20145147
16.
MYCN oncoprotein targets and their therapeutic potential.
Cancer Lett
; 293(2): 144-57, 2010 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-20153925
17.
p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma.
Cell Cycle
; 6(21): 2685-96, 2007 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17912039